EA022317B1 - Medication possessing antiviral, antibacterial, antifungal, burn-treating action and method for obtaining the same - Google Patents

Abstract

The invention relates to medicine and pharmacology, in particular to levorin antibiotic-containing medications, possessing chemotherapeutic activity against pathogens of viral, staphylococcal and fungal infections, as well as to substances, possessing burn-treating properties both in vitro and in vivo, cosmetic and hygienic action. The set task is achieved by that the medication possessing antiviral, antibacterial, antifungal, burn-treating action, based on dimethylsulphoxide-containing levorin, in accordance with the invention additionally includes citral, and comprises levorin Aas levorin, with the following component ratio, wt.%: levorin A- 0.001-5; citral - 0.1-50; dimethylsulphoxide - the remainder. The task of the invention also comprises development of a method for obtaining medication possessing antiviral, antibacterial, antifungal, burn-treating, cosmetic and hygienic action. The set task is achieved by that as levorin taken is levorin A, which is dissolved in citral with further addition of dimethylsulphoxide solution with additional introduction into the mixture of at least one more component, such as pharmaceutically acceptable active substance, and/or flavour, and/or dye, and/or thickening agent, with the following ratio, wt.%: medication - 5.0-50; additionally pharmaceutically acceptable components - the remainder.

Description

The invention relates to medicine and pharmacology, in particular to medicines containing the antibiotic levorin, which have chemotherapeutic activity against pathogens of viral and staphylococcal infections, deep systemic mycoses and yeast-like fungi, as well as substances that have anti-burn properties ΐπ νΐΐΓΟ and οπ as well as cosmetic action and the method for their preparation.

Known drug levorin used against pathogens of deep systemic mycoses and yeast-like fungi [1]. Levorin - an antibiotic with a gross formula Ο ₅₉ Η ₉₃ Ν ₂ Ο ₂₂ belongs to the subgroup of aromatic heptaenes. Levorin is produced by microorganisms 81ger1usus 8 Γονοπίπ.

In the clinical use of levorin powder, there are a number of disadvantages: 1) a high concentration of levorin to achieve a therapeutic effect; 2) the presence of a powder form, which has a low membrane activity; 3) a sufficiently long period of treatment - 10-15 days; 4) insufficient resorption of the antibiotic levorin to quickly and completely suppress microorganisms; 5) lack of stability of levorin in powder form; 6) poor selectivity of the action of the powdered form of levorin on pathogenic microorganisms.

As a prototype taken patent ΑΖ ί 2000 02 13 (99/00 1287), in which levorin is in a solution of dimethyl sulfoxide (DMSO) in the following ratios of components, wt.%: Levorin 0.01-2; DMSO - the rest. In the specified prototype, the drug is intended for the treatment of fungal, purulent and viral infections. The disadvantage of this drug is the low selectivity of action in relation to pathogenic cells, a low degree of resorption due to the high surface tension of the solution, a rapid loss of pharmacological properties, i.e. short shelf life.

The objective of the invention is to expand the arsenal of drugs; this is necessary in the treatment of viral, staphylococcal and fungal infections, thermal and chemical burns of both ΐπ νΐΐΓΟ and ΐπ νΐνο, as well as increasing the effectiveness of treatment, reducing the concentration of the substance used to achieve maximum treatment effectiveness, increasing the degree of drug resorption and its selective effect on pathogenic microorganisms.

The problem is achieved in that the drug having antiviral, antibacterial, antifungal, anti-burn action based on levorin, containing dimethyl sulfoxide, according to the invention additionally includes citral, and as levorin contains levorin A ₂ in the following ratio, wt.%:

Levorin A ₂ 0.001 - 5

Citral 0.1-50

Dimethyl sulfoxide rest.

Moreover, according to the invention, it can additionally contain in the required amount at least one more component, such as a pharmaceutically acceptable active substance, and / or flavoring, and / or dye and / or thickener, in the following ratio, wt.%:

drug 5.0–50.0%; additional pharmaceutically acceptable components; rest.

The medicament according to the invention may also have a cosmetic and hygienic effect.

The objective of the invention is also the creation of a method that provides high quality obtained antibiotic drugs.

The problem is achieved in that in the method for producing a medicinal product having antiviral, antibacterial, antifungal, anti-burn action, including the dissolution of levorin in a solvent, according to the invention, levorin A _{2 is} taken as levorin, which is dissolved in citral followed by the addition of a dimethyl sulfoxide solution in the following ratio components, wt.%:

Levorin A ₂ 0.001 - 5

Citral 0.1-50

Dimethyl sulfoxide rest.

The proposed method also provides the possibility of additionally introducing into this mixture at least one more component, such as a pharmaceutically acceptable active substance, and / or flavoring, and / or coloring agent and / or thickener, with the additional component being introduced:

either simultaneously with the introduction of a solution of citral-DMSO with an antibiotic substance, or the basis of a mixture with a solution of citral-DMSO with an antibiotic substance, or after a mixture of citral-DMSO with an active antibiotic substance, or in a solution of citral-DMSO with antibiotic substance to form a mixture with the base. The use of the pharmaceutical composition of citral with DMSO as an active principle of an antibiotic drug by dissolving at least one antibiotic or its derivative or salt in it allows the crystal structure of the antibiotic substance to be transformed into the most active molecular form, increasing the activity of the antibiotic as due to the molecular form of the antibiotic, and also due to the manifestation of the pharmacological properties of citral itself, which provides fast penetration the appearance of an antibiotic substance in the tissues, blood vessels and body fluids, during treatment, reduce the amount of antibiotic consumed and reduce the side and negative manifestations associated with the use of antibiotics, since it ensures the rapid and complete removal of antibiotic substances from the body.

DMSO belongs to the class of secondary alcohols with a gross formula - (CH ₃ ) ₂ §O [2]. DMSO is approved for clinical use by the Pharmacological Committee of Ukraine on October 31, 1996, registration number T / 97/29/3 (see the Instructions for medical use of DMSO in the appendix). He also underwent clinical trials in Russia, Ukraine, Belarus, Azerbaijan and is used in the treatment of inflammatory processes [3]. DMSO is a liquid at a temperature above 18 ° C, and at a lower temperature a crystalline substance at a boiling point of 189 ° C, b 1.1 (20 ° C). It mixes well with water, a solvent for many organic substances, low toxicity for animals and humans; the skin is not irritating, approved for use in veterinary medicine and medicine; transports the drugs dissolved in it through the skin. The dielectric constant of DMSO is ε = 18.9. The DMSO dielectric constant is between water ε = 80 and fats ε = 2. Due to this feature, DMSO is soluble in both water and fats.

The macrolide heptaene antibiotic levorin is heterogeneous in composition and includes two aromatic heptenes that are similar in chemical structure but not identical in their properties: levorin A and levorin B [1]. Levorin A is less toxic and has a higher biological activity than levorin B. In the analysis, it turned out that levorin A is not an individual substance, but is a mixture of several components - Az, A ₁ , A ₂ , A ₃ , Ad. Levorin A ₂ is the main and one of the effective components of the antibiotic mixture of levorin A (see tab. 1, 2). The choice of levorin A ₂ as the active component of the drug is due to the fact that it induces ideal permeability in the cell membranes for potassium cations and has a high selectivity for the action of steroid-containing membranes of pathogenic cells.

To achieve a high therapeutic effect, it is necessary to transport antibiotic molecules into the cells of tissues and body fluids to a sufficiently large depth of the epithelial layer. The degree of resorption of the substance into organs and tissues depends on the surface tension of the solution in which the active substance is dissolved. The lower the surface tension of the solution, the higher the degree of resorption of the substance dissolved in it. Citral is an additional component in the composition of the claimed medicinal product, which affects the surface tension of aqueous solutions. Citral is an aliphatic terpene aldehyde.

Due to the difference in dielectric constant (see Table 3), citral is poorly soluble in water. Once in water, citral forms a colloidal dispersed system and has a significant effect on the surface tension of water. The introduction of levorin A ₂ at a concentration of 0.1-20 mg / ml in a solution of pure DMSO weakly affects its surface tension. The surface tension of aqueous solutions decreases significantly depending on the concentration of compounds introduced into the water composition. The combined introduction of the individual components of DMSO and citral into water more effectively reduces the surface tension of the solution than DMSO in combination with levorin A ₂ .

The presence of an aqueous and / or pharmaceutically acceptable alcohol and / or fat and / or polymer base in an antibiotic drug in combination with an active principle allows you to get an acceptable dosage form - drops, medicine, injection, ointment, etc. in a form convenient for application and the necessary consistency. As an active principle, a pharmaceutical composition is used consisting of a solution of at least one antibiotic or its derivative or salt in citral with DMSO.

Citral (3,7-dimethyl-2,6-octadienal) is a monoterpene acyclic aldehyde, exists in the form of two isomers: trans-citral (the so-called geranial) and cis-citral (the so-called neral). Citral, present in natural essential oils, is a mixture of two isomers with a predominance of geranial. Citral is a colorless or light yellow viscous liquid with a strong smell of lemon. Citral is found in the essential oil of lemon sorghum (lemongrass oil, up to 85%), lemon, eucalyptus and some other essential oils. Citral is used as a fragrant in perfumes, as a flavoring in the food industry. It is part of the medication for the eyes, lowers blood pressure, has an antiseptic, analgesic and anti-inflammatory effect, and stimulates the corneal epithelization process.

With a low content of citral and DMSO with an antibiotic substance, for example, in water, it allows people and animals to use such water for drinking, and even with 0.001% an active preventive effect is achieved. Intermediate ratios are selected depending on the type and purpose

- 2 022317 drugs. For example, the presence of 20-60% of citral in DMSO with an antibiotic substance in 80-40% of an oil or polymer base makes it possible to obtain an antibiotic ointment for external use.

The introduction of any other pharmaceutically acceptable active substance compatible with antibiotics into the antibiotic drug allows to expand the range of drugs and eliminate the need to use a large amount of the drug during treatment. The additional introduction of a pharmaceutically acceptable flavor and / or dye allows you to get a pleasant smell and color of the drug, as well as expand the range of drugs and make them convenient for recognition and use, especially in the treatment of children with very sensitive sense of smell. The introduction of a pharmaceutically acceptable thickener allows you to get the necessary consistency of the drug in cases where a liquid or insufficiently viscous consistency of the drug is unacceptable or not desirable, for example, to obtain slowly absorbable pills or plates.

The biological activity of some derivatives of polyene antibiotics was studied by the method of bilayer lipid membranes: sodium salt of levorin, sodium salt of acetyl-levorin, sodium salt of succinyl-levorin, sodium salt of nystatin, sodium salt of mycoheptin, sodium salt of amphotericin B. In addition, the biological activity of other derivatives of other amphetericin B. was studied. polyene antibiotics modified in various parts of the lactone ring. For example, amphotericin B is Ν-trimethylamphotericin B (methylated amphotericin B), Ν, Ν, Ν-trimethylamphotericin B (metamphocin), methyl ester of amphotericin B, N is acetyl amphotericin B, alkyl derivatives (methyl, ethyl, propyl, butyl) and levorin A ₂ [3]. All studied derivatives of polyene antibiotics turned out to be biologically active compounds [9]. Each of these derivatives can be introduced into the composition of the claimed medicinal product both individually and in combination with levorin A ₂ .

When implementing the method of preparing an antibiotic drug, it is first necessary to convert the antibiotic substance from a powder form (crystalline) to a molecular form. In this case, the conversion of the antibiotic substance into the form most effective for pharmaceutical purposes is achieved, which can subsequently be actively mixed with any other pharmaceutically acceptable bases and substances in the preparation of medicines. The drug is obtained by dissolving 1 mg - 50 g of Levorin A ₂ powder in 100 ml of citral followed by the introduction of DMSO in 1 L.

Depending on the task, a certain amount of dry powder of levorin A ₂ with a biological activity of 25000-30000 IU / mg is taken and fractionally introduced into the citral solution. Each additive is thoroughly mixed and after the complete introduction of levorin A2 into the citral solution, the resulting pharmaceutical composition is aged for 3 hours in a dry, dark place at room temperature. Thus, the pharmaceutical composition obtained in the first step is then also fractionally introduced into the DMSO solution. Each additive is thoroughly mixed. After the complete introduction of levorin A ₂ with citral into the DMSO solution, the liquid is filtered and stored in a dark, cool place. The result is a stock solution of the drug, ready for use. The shelf life of the mother liquor is 10 years.

The created drug eliminates all the disadvantages inherent in the prototype. So, for example, to achieve the maximum therapeutic effect, the concentration of levorin A _{2 is} reduced by 10 times, the presence of levorin A2 in a solution of citral and DMSO gives a high membrane activity, the treatment time of the corresponding disease is reduced by 3-5 times, there is a high resorption of the antibiotic levorin A2 in solution citral with DMSO and high selectivity of action on pathogenic microorganisms.

It is known that antibiotics belonging to the class of macrolide heptaene polyene compounds as a therapeutic form do not exist in the form of a solution of citral in DMSO, which reduces their effectiveness and selectivity of action in the treatment of relevant diseases. From the foregoing, therefore, we can conclude that the proposed drug is a new dosage form of PA, in particular levorin A ₂ and derivatives of PA, and the proposed solution meets the criterion of novelty. Analysis of the qualitative composition of the proposed tool suggests that the components included in the proposed drug are known and are widely used in medicine. However, their combined use in such a combination and the therapeutic effect achieved with this is unknown and new. When using the proposed medicinal product, until now unknown properties have been identified. So, it turned out that the proposed drug has an effective therapeutic effect not only on pathogenic fungal cells, but also on viral and bacterial infections, and also has anti-burn properties (see Test reports in the application Examples of use). A solution of levorin A ₂ and PA derivatives in citral with DMSO is stable for more than 10 years when stored in a dry, dark and cool place.

The claimed drug does not have a side effect, in particular, it does not inhibit peripheral blood, is absolutely non-toxic (see Test reports). Lethal dose

- 3 022317

Lb ₅₀ for mice is 1000 mg / kg. With daily two-time treatment, the infectious process ends by day 3 (see Examples of use), and when using tablets and levorin ointment, by 10-15 days. Within 'L h after application of the drug in the specified form and in the specified concentration to the damaged surface of the skin, itching, burning and pain disappear, does not irritate the skin. It can also be used as a medicine when diluted with water in various proportions (see Test reports).

Examples of specific performance.

The invention passed the stage of testing on laboratory animals and on individual patient volunteers (see Test Reports and Application Example in the appendix). We give examples of the specific use of the drug in individual patients.

Examples of the use of the proposed drug against viral infections.

1. For 10 years, the patient suffered from the Negrekk / Oh virus, in which in the autumn-winter months the appearance of a bright red inflammatory nimbus on the nasal mucosa, accompanied by severe pain, was observed. Treatment with salicylic drugs, geoxysine, and some antibiotics failed. After daily two-time application of the proposed drug on the inflammatory surface of the skin (morning and evening) for 3 days, it ended in complete recovery.

2. A young girl of 20 years turned to the author of the invention with complaints of serious changes in the anatomical structure of the face. Doctors who examined the patient found that the main cause of the disease is the Negrek virus / Oh. Due to her illness, the girl could not attend classes at the Medical University, where she studied in the second year of the Faculty of Medicine, and therefore was hospitalized at home. Despite the use of modern drugs, the treatment did not give a positive effect. In the future, with the aim of treating a viral disease, the claimed preparation was used. After a daily two-time application of the proposed drug on the inflammatory surface of the skin of the face (morning and evening) for 3 days, it ended with a complete restoration of the structure of the skin of the face - the anatomical curvature disappeared and then within 3 weeks all clinical manifestations of the disease completely disappeared.

3. A young girl of 22 years turned to the author of the invention with complaints of serious changes in the structure of her face - there were abrasions, cracks. The doctors who examined the patient were not able to establish an accurate diagnosis of the occurrence of the disease and made only the assumption that the main cause of the disease may be a virus of an unknown nature. Despite the use of modern drugs, the treatment did not give a positive effect. The girl turned to the author of the invention with a request to use the claimed drug for treatment. After examination, she was recommended to use the drug twice daily in the morning and evening. The swab containing an aqueous solution of the proposed drug, wiped the inflammatory surface of the skin of the face. Using the drug for 4 weeks, the girl completely restored the structure of her skin - abrasions and cracks completely disappeared, and after that all clinical manifestations of the disease disappeared.

Examples of the use of the proposed drug against staphylococcal infections.

1. A young girl of 24 years turned to the author of the invention with complaints of a change in the skin of the face, which was strewn with purulent acne. Despite the appropriate courses of treatment prescribed by doctors, the clinical manifestations of the disease did not disappear. On the recommendation of the authors, she used an aqueous solution of the proposed drug (1 part of the proposed drug, diluted in 9 parts of distilled water). In the morning and evening she wiped her face with this solution using a cotton swab moistened with it. Then a thin layer of cream was applied to the skin containing the proposed drug in the ratio of 1 part of the proposed drug and 5 parts of the ointment base. Following a diet, after 7 days all clinical manifestations of the disease disappeared completely.

2. A young girl of 27 years turned to the author of the invention with complaints of unbearable pain in the throat due to staphylococcal infection. Rinsing with various antibiotics, as well as a course of treatment with intramuscular injection of various antibiotics did not give the desired result. Rinsing with an aqueous solution of the proposed drug several times a day relieved inflammation in the nasopharynx and staphylococcal infection was completely suppressed.

3. A young woman suffered from intolerable pains of the index finger due to a purulent infection under the nail. The course of treatment for several days with the drugs corresponding to this disease did not give any results. The finger is swollen, accompanied by severe pain. After applying the initial solution of the proposed drug purulent infection was suppressed for 3 days.

Examples of the use of the proposed drug against fungal infections.

1. The patient for 4 years suffered from rubromycosis of the foot. Treatment with drugs corresponding to this disease did not give an effect. After applying the proposed drug to the damaged surface of the skin 2 times a day in the morning and in the evening for several days, 4 022317 ended in complete recovery.

2. The patient for a long time suffered from rubromycosis of the nail of the thumb of the right hand. The finger was infected, inflamed. The disease was accompanied by acute itching and pain. Treatment with drugs appropriate for this disease did not produce results. After applying the proposed drug in the morning and evening for several days, the inflammation subsided, the purulent focus was eliminated and the nail was completely regenerated without surgery.

3. The patient complained of acute burning sensations and itching between the toes of the right foot. On examination, it turned out that the patient develops interdigital erosion of candidal origin. The use of known antifungal ointments of nystatin, levorin, mycoheptin, amphotericin B to patients showed a relative effect, however, the treatment with these antibiotics took a long time for 15 days and did not contribute to the achievement of the expected result. The use of the proposed drug at its first application to the damaged surface of the skin for 1 h completely removed the sensation of pain, itching and burning. Application of the proposed drug 2 times a day in the morning and evening on the sore surface of the skin led to the complete cure of the patient within a few days.

Examples of the use of the proposed drug for thermal burns.

1. Patient D. filed complaints in connection with a thermal burn of 2-1 degrees of the left leg from the heel to the knee joint due to the ingress of boiling water, which was intended for washing clothes. Urgent treatment of the burn surface with the German foaming aerosol preparation Panzenol for 6 hours after receiving the burn did not give any results. All the time, patient D. felt severe, almost intolerant pain. Subsequent treatment of the burn surface with the claimed preparation (1 part of the proposed drug was diluted in 10 parts of distilled water) led to the removal of all pain sensations after 30 minutes and complete skin regeneration over the next 2 weeks. During all this time no purulent discharge was found.

2. Patient E. complained of general malaise, lethargy, fatigue and headaches. A blood test showed that the patient had an increased white blood cell count and a lower red blood cell count. It turned out that the patient in 1986 was part of the Azerbaijan Brigade, which arrived in Chernobyl to provide assistance to those affected by the accident at the Chernobyl nuclear power plant. During his stay in Chernobyl, the patient received a certain dose of thermal burn and radiation exposure. The use of the proposed medicinal product by the patient in drops of 20 drops per 2 tablespoons of water 3 times a day for 2 weeks and the application of an aqueous solution of the proposed medicinal product on the burned skin surface completely eliminated all undesirable symptoms. After taking the proposed drug in a blood test, the composition of the white blood cell and red blood cell was normal.

3. A young girl of 26 years turned to the author of the invention with complaints of unbearable pain resulting from a sunburn on her skin on the beach. Despite the use of various anti-burn creams, the desired relief did not come. As a result of applying an aqueous solution of the proposed drug in a ratio of 1 part of the proposed drug, diluted in 10-20 parts of water, on the burned surface of the skin for 15-20 minutes, all pain and burning sensation were completely removed.

A comparative description of the effective effective concentrations of the proposed drug with some antiviral, antibacterial and antifungal drugs showed that the claimed active principle is many times more effective, and the spectrum of its biological action is much wider than similar analogues existing at the moment (see table 4).

Table 1

The quantitative ratio of components A ₀ , A ₁ , A ₂ , A ₃ in preparations of levorin A obtained during the biosynthesis of various variants of AsBiotusek 1suop5 [Tsyganov, Yakovleva, 1970]

- 5,022,317

table 2

The activity of the components Az, A _b A ₂ , A ₃ [Tsyganov, Yakovleva, 1970]

(Name (drug The diffusion method in agar, ED / ml Serial method dilutions, mcg / ml | and about 2040 + 93 0.4-0.6 (but, one...... .................... 15900 + 274 0.06-0.07 b .......... 25800 ± 540 0.02-0.04 L g. .. 37100+ 1080 0.01-0.02

Basic physical and chemical properties of water, DMSO and citral

Table 3

Physicochemical parameters WATER DMSO CITRAL one Molecular Weight (g-mol ' ¹ ) 02/18 78.13 152.2 2 Density at 20 ° C (g-cm ' ³ ) 0.9982 1.1014 0.890 3 Melting Point (° C) 0.00 18.4 - 4 Boiling Point (° C) 100.00 189.0 228’s 5 Refractive index at 20 ° C 1.3329 1.4770 1.4838 6 Up, pull. at 20 ° С (10' ^ Nm ¹ ) 72.75 46.2 29.4 7 Viscosity at 20 ° C (10 ' ³ -Pa-s) 1.002 2.20 3.40 8 Dielectric constant at 20 ° С 80.20 48.9 4.36

Table 4

Comparative characteristics of the current concentrations of the proposed drug with some antiviral, antibacterial and antifungal drugs

PATENT A DRUG ANTI-VIRUS DRUGS ANTIVACTABLE- REAL DRUGS ANTIFUNGIC DRUGS Proposed medicinal means 1. Intramuscularly 0.05 mg / kg 2. Oral 3 mg 3 times in a day 1.3IDOVUDIN - 100 mg capsules orally 6 times a day (0.6 gr.) 2. BETAFERON - Intramuscularly, in 1 the bottle contains 10 000 000 units 3. ARBIDOL - 0.2 g tablets 4. ALPIZARIN - 0.1 g tablets 5. RETROVIR - 250 mg capsules and intravenous injection 250 mg each 6. Acyclovir - Intravenously 1 ampoule - 250 mg 1. JOSAMITSIN 1-2 gr. Oral 3 once a day 2. Doxycycline - 200 mg orally. 3. CABENICILLIN- 5 intramuscularly column every 4-6 hours 4. CARFETSILLIN - Take orally by 1 g 3 times a day 5. KLACID - Orally 1 g. 2 once a day for 6 months and more 6. Clindamycin Inside 0.5 gr. 1. DIFLUKON- 400 mg orally. 2. MEDOFLKJON- 200 mg capsules 3. MIKOMAX - 159 mg capsules 4. MIKOSIST - 150 mg capsules.i infusion solution 200 mg / SO ml 5. MIKOFLYUKAN- 150 mg tablets Infusion Solution 200 mg 6. AMPHOTERICIN IN- Intravenously - at 1 bottle of 50 000 PIECES or about 70 mg (750 PIECES = 1 mg)

- 6,022,317

Literature

1. Levorin and its clinical use. 1970. - Proceedings of LNIIA. Graduation of W. edited by V. Tsyganov Leningrad, s. 1-157.

2. Wu Ζ., Οιιίίηη R. 1994. Οίιηαίινί 8u1pbokh1be: and gsuuu £ 8 8 ар ар й й се се се се се се 11 ю. - Vyksheise Keroyk, ν. 14, p. 259-281.

3. Muravyov Yu. 1989. Dimethyl sulfoxide in the treatment of rheumatic diseases (clinical and experimental research). - Institute of Rheumatology of the Academy of Medical Sciences of Russia. Moscow. Abstract. Doctoral dissertation, p. 1-44.

Claims (7)

CLAIM 1. Drug with antiviral, antibacterial, antifungal, anti-burn action on the basis of levorin, containing dimethyl sulfoxide, characterized in that the agent includes citral, and as levorin contains levorin A ₂ or its salt in the following ratio, wt.%: Levorin A ₂ - 0.001-5.0; citral - 0.1-50.0; dimethyl sulfoxide - the rest. 2. The drug according to claim 1, characterized in that it further comprises at least one active antibiotic agent. 3. The drug according to claims 1 and 2, characterized in that it additionally contains at least one pharmaceutically acceptable excipient in the following ratio of components, wt.%: Drug - 5.0-50.0; pharmaceutically acceptable excipients - the rest. 4. Drug in PP.1-3, characterized in that the agent has a cosmetic and hygienic effect. 5. A method of obtaining a drug according to claim 1, comprising dissolving levorin in a solvent, characterized in that levorin A ₂ or its salt is taken as levorin, which is injected into the solvent citral, followed by the addition of a solution of dimethyl sulfoxide. 6. The method according to claim 5, characterized in that at least one active antibiotic agent is further added to the drug. 7. The method according to claims 5 and 6, characterized in that at least one pharmaceutically acceptable excipient is further added to the drug.